DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Aurobindo Pharma Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·5 Oct 2026, 7:38 am

Aurobindo Pharma

Aurobindo Pharma has informed stock exchanges that it has received a certificate under SEBI's Depositories and Participants Regulations, 2018. This regulatory filing confirms the company's compliance with the specified norms governing its depository operations.

This disclosure is primarily a procedural update for investors. It confirms that the company's shareholding records are being maintained in accordance with the latest SEBI regulations, ensuring transparency in the dematerialization and settlement of securities.

Investors should note that this is a routine compliance announcement. It does not indicate any significant operational change or financial development. The focus now shifts to the company's upcoming quarterly performance and its ability to sustain growth in the competitive generic drug market.